Hem › Multipelt myelom › Tennessee › Nashville

Kliniska studier för Multipelt myelom i Nashville, TN

32 studier för Multipelt myelom söker deltagare vid platser i och runt Nashville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.

Officiell studietext (engelska)

Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

RekryterarFas 3

Research Site, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT07391657

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

RekryterarFas 3

Tennessee Oncology, PLLC, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

RekryterarFas 1

Research Site, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07073547

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

RekryterarFas 3

SCRI Oncology Partners, Nashville
Vanderbilt University Medical Center, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

RekryterarFas 3

Henry-Joyce Cancer Clinic, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05552222

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

RekryterarFas 4

Sarah Cannon Research Institute, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05201781

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

RekryterarFas 1/2

Sarah Cannon Research Institute, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT07116616

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

RekryterarFas 2/3

SCRI Oncology Partners /ID# 278353, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

RekryterarFas 2

Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville

Ålder 12 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

RekryterarFas 2

Tennessee Oncology, Nashville
Vanderbilt University Medical Center, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT06297226

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

RekryterarFas 2

SCRI Oncology Partners, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 4 sep. 2026 · NCT07637578

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

RekryterarFas 1

Tennessee Oncology, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 28 aug. 2026 · NCT06375044

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

RekryterarFas 1/2

Research Site, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 27 aug. 2026 · NCT07681596

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

RekryterarFas 2

GSK Investigational Site, Nashville

Ålder 18 och äldre · Alla kön · Uppdaterad 25 aug. 2026 · NCT07227311

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

RekryterarFas 3

Ascension St. Thomas Hospital, Nashville
Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
och 2 fler

Ålder 18 och äldre · Alla kön · Uppdaterad 24 aug. 2026 · NCT06152575